Platelet dysfunction in central obesity
Tóm tắt
Từ khóa
Tài liệu tham khảo
National Task Force on the Prevention and Treatment of Obesity, 2000, Overweight, obesity, and health risk, Arch Intern Med, 160, 898, 10.1001/archinte.160.7.898
Després, 2007, Cardiovascular disease under the influence of excess visceral fat, Crit Pathw Cardiol, 6, 51, 10.1097/HPC.0b013e318057d4c9
Ritchie, 2007, The link between abdominal obesity, metabolic syndrome and cardiovascular disease, Nutr Metab Cardiovasc Dis, 17, 319, 10.1016/j.numecd.2006.07.005
Alberti, 2005, The metabolic syndrome – a new worldwide definition, Lancet, 366, 1059, 10.1016/S0140-6736(05)67402-8
Mertens, 2002, Obesity, haemostasis and the fibrinolytic system, Obes Rev, 3, 85, 10.1046/j.1467-789X.2002.00056.x
Nieuwdorp, 2005, Hypercoagulability in the metabolic syndrome, Curr Opin Pharmacol, 5, 155, 10.1016/j.coph.2004.10.003
Michelson, 2003, How platelets work: platelet function and dysfunction, J Thromb Thrombolysis, 16, 7, 10.1023/B:THRO.0000014586.77684.82
Lefkovits, 1995, Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine, N Engl J Med, 332, 1553, 10.1056/NEJM199506083322306
Gawaz, 2004, Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium, Cardiovasc Res, 61, 498, 10.1016/j.cardiores.2003.11.036
Massberg, 2003, A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo, J Exp Med, 197, 41, 10.1084/jem.20020945
Jokl, 1994, Platelet plasminogen activator inhibitor 1 in patients with type II diabetes, Diabetes Care, 17, 818, 10.2337/diacare.17.8.818
Jokl, 1995, Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes, Diabetes Care, 18, 1150, 10.2337/diacare.18.8.1150
Massberg, 1998, Platelet–endothelial cell interactions during ischemia/reperfusion: the role of P-selectin, Blood, 92, 507, 10.1182/blood.V92.2.507
Cyrus, 2002, Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice, Circulation, 106, 1282, 10.1161/01.CIR.0000027816.54430.96
Praticò, 2001, Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice, Proc Natl Acad Sci U S A, 98, 3358, 10.1073/pnas.061607398
Cayatte, 2000, The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis, Arterioscler Thromb Vasc Biol, 20, 1724, 10.1161/01.ATV.20.7.1724
Huo, 2004, Role of platelets in the development of atherosclerosis, Trends Cardiovasc Med, 14, 18, 10.1016/j.tcm.2003.09.007
Theilmeier, 2002, Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia, Blood, 99, 4486, 10.1182/blood.V99.12.4486
Nassar, 2003, Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells, J Biol Chem, 278, 6187, 10.1074/jbc.M208894200
Henn, 1998, CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells, Nature, 391, 591, 10.1038/35393
Lindmark, 2000, Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression, Arterioscler Thromb Vasc Biol, 20, 2322, 10.1161/01.ATV.20.10.2322
Mach, 1998, Reduction of atherosclerosis in mice by inhibition of CD40 signalling, Nature, 394, 200, 10.1038/28204
Moncada, 2006, Nitric oxide and the vascular endothelium, Handb Exp Pharmacol, 213, 10.1007/3-540-32967-6_7
Radomski, 1993, The biological and pharmacological role of nitric oxide in platelet function, Adv Exp Med Biol, 344, 251, 10.1007/978-1-4615-2994-1_20
Maurice, 1990, Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP, Mol Pharmacol, 37, 671
Freedman, 1997, Nitric oxide released from activated platelets inhibits platelet recruitment, J Clin Invest, 100, 350, 10.1172/JCI119540
Schwarz, 2001, Taming platelets with cyclic nucleotides, Biochem Pharmacol, 62, 1153, 10.1016/S0006-2952(01)00760-2
Napoli, 2006, Nitric oxide and atherosclerosis: an update, Nitric Oxide, 15, 265, 10.1016/j.niox.2006.03.011
Anfossi, 2006, Platelet resistance to the anti-aggregating agents in the insulin resistant states, Curr Diabetes Rev, 2, 409, 10.2174/1573399810602040409
Chirkov, 2007, Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier?, Pharmacol Ther, 116, 287, 10.1016/j.pharmthera.2007.06.012
Ades, 2008, The influence of obesity and consequent insulin resistance on coronary risk factors in medically treated patients with coronary disease, Int J Obes, 32, 967, 10.1038/ijo.2008.6
Vinik, 2001, Platelet dysfunction in type 2 diabetes, Diabetes Care, 24, 1476, 10.2337/diacare.24.8.1476
Colwell, 2003, The platelet in diabetes: focus on prevention of ischemic events, Diabetes Care, 26, 2181, 10.2337/diacare.26.7.2181
Trovati, 2002, Mechanisms involved in platelet hyperactivation and platelet–endothelium interrelationships in diabetes mellitus, Curr Diab Rep, 2, 316, 10.1007/s11892-002-0020-7
Yetkin, 2008, Mean platelet volume not so far from being a routine diagnostic and prognostic measurement, Thromb Haemost, 100, 3, 10.1160/TH08-05-0336
Coban, 2005, The mean platelet volume in patients with obesity, Int J Clin Pract, 59, 981, 10.1111/j.1742-1241.2005.00500.x
Muscari, 2008, Determinants of mean platelet volume (MPV) in an elderly population: relevance of body fat, blood glucose and ischaemic electrocardiographic changes, Thromb Haemost, 99, 1079, 10.1160/TH07-12-0712
Tavil, 2007, Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease, Thromb Res, 120, 245, 10.1016/j.thromres.2006.10.005
Samocha-Bonet, 2008, Platelet counts and platelet activation markers in obese subjects, Mediators Inflamm, 10.1155/2008/834153
Meade, 1985, Epidemiological characteristics of platelet aggregability, Br Med J, 290, 428, 10.1136/bmj.290.6466.428
Davì, 2002, Platelet activation in obese women: role of inflammation and oxidant stress, JAMA, 288, 2008, 10.1001/jama.288.16.2008
De Pergola, 2008, sP-selectin plasma levels in obesity: association with insulin resistance and related metabolic and prothrombotic factors, Nutr Metab Cardiovasc Dis, 18, 227, 10.1016/j.numecd.2006.09.010
Desideri, 2003, Effects of obesity and weight loss on soluble CD40L levels, JAMA, 289, 1781, 10.1001/jama.289.14.1781
Gokulakrishnan, 2006, Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome – the Chennai Urban Rural Epidemiology Study, Metabolism, 55, 237, 10.1016/j.metabol.2005.08.019
Angelico, 2006, Enhanced soluble CD40L in patients with the metabolic syndrome: relationship with in vivo thrombin generation, Diabetologia, 49, 1169, 10.1007/s00125-006-0222-7
Santilli, 2007, CD40/CD40L system and vascular disease, Intern Emerg Med, 2, 256, 10.1007/s11739-007-0076-0
George, 2008, Microparticles in vascular diseases, Thromb Res, 122, S55, 10.1016/S0049-3848(08)70020-3
Barry, 1998, Modulation of monocyte–endothelial cell interactions by platelet microparticles, J Clin Invest, 102, 136, 10.1172/JCI2592
Merten, 1999, Platelet microparticles promote platelet interaction with subendothelial matrix in a glycoprotein IIb/IIIa-dependent mechanism, Circulation, 99, 2577, 10.1161/01.CIR.99.19.2577
Nomura, 1995, Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus, Atherosclerosis, 116, 235, 10.1016/0021-9150(95)05551-7
Murakami, 2007, Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity, Thromb Res, 119, 45, 10.1016/j.thromres.2005.12.013
Falcon, 1988, The platelet insulin receptor: detection, partial characterization, and search for a function, Biochem Biophys Res Commun, 157, 1190, 10.1016/S0006-291X(88)81000-3
López-Aparicio, 1992, Insulin induced phosphorylation and activation of the cGMP-inhibited cAMP phosphodiesterase in human platelets, Biochem Biophys Res Commun, 186, 517, 10.1016/S0006-291X(05)80838-1
Trovati, 1988, Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo, Diabetes, 37, 780, 10.2337/diab.37.6.780
Trovati, 1989, Insulin reduces platelet sensitivity to platelet activating factor in washed human platelets resuspended in a calcium-free medium, Diab Nutr Metab, 2, 151
Trovati, 1990, Physiological insulin concentrations reduce platelet sensitivity to adrenaline in vivo, vol. 10, 166
Russo, 2002, Comparison between the effects of the rapid recombinant insulin analog aspart and those of human regular insulin on platelet cyclic nucleotides and aggregation, Thromb Res, 107, 31, 10.1016/S0049-3848(02)00182-2
Russo, 2003, Comparison between the effects of the rapid recombinant insulin analog Lispro (Lys B28, Pro B29) and those of human regular insulin on platelet cyclic nucleotides and aggregation, Thromb Res, 109, 323, 10.1016/S0049-3848(03)00255-X
Touyz, 1994, Blunted inhibition by insulin of agonist-stimulated calcium, pH and aggregatory responses in platelets from hypertensive patients, J Hypertens, 12, 1255, 10.1097/00004872-199411000-00008
Hiramatsu, 1987, Reduction of platelet aggregation induced by euglycaemic insulin clamp, Diabetologia, 30, 310, 10.1007/BF00299023
Westerbacka, 2002, Inhibition of platelet–collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity, Arterioscler Thromb Vasc Biol, 22, 167, 10.1161/hq0102.101546
Trovati, 1994, Insulin increases guanosine-3′5′-cyclic monophosphate in human platelets. A mechanism involved in the insulin anti-aggregating effect, Diabetes, 43, 1015, 10.2337/diab.43.8.1015
Trovati, 1996, The insulin-induced increase of guanosine-3′5′-cyclic monophosphate in human platelets is mediated by nitric oxide, Diabetes, 45, 768, 10.2337/diab.45.6.768
Trovati, 1997, Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3′ 5′-cyclic monophosphate and adenosine-3′ 5′-cyclic monophosphate, Diabetes, 46, 742, 10.2337/diab.46.5.742
Trovati, 1998, Insulin, insulin resistance and platelet function: similarities with insulin effects on cultured vascular smooth muscle cells, Diabetologia, 41, 609, 10.1007/s001250050958
Butt, 1994, cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets, J Biol Chem, 269, 14509, 10.1016/S0021-9258(17)36652-8
Yamanishi, 1983, Effect of cyclic AMP on cytoplasmic free calcium in human platelets stimulated by thrombin: direct measurement with quin2, Thromb Res, 32, 183, 10.1016/0049-3848(83)90029-4
Kawahara, 1984, Inhibitory action of guanosine 3′5′-monophosphate on thrombin-induced calcium mobilization in human platelets, Thromb Res, 33, 203, 10.1016/0049-3848(84)90181-6
Ferreira, 2004, IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi, J Biol Chem, 279, 3254, 10.1074/jbc.M305474200
Trovati, 1995, Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients, Diabetes, 44, 1318, 10.2337/diab.44.11.1318
Ferreira, 2006, Platelet inhibition by insulin is absent in type 2 diabetes mellitus, Arterioscler Thromb Vasc Biol, 26, 417, 10.1161/01.ATV.0000199519.37089.a0
Anfossi, 1998, Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM, Diabetes Care, 21, 121, 10.2337/diacare.21.1.121
Anfossi, 2004, Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity, Eur J Clin Invest, 34, 482, 10.1111/j.1365-2362.2004.01370.x
Chirkov, 1996, Suppressed anti-aggregating and cGMP-elevating effects of sodium nitroprusside in platelets from patients with stable angina pectoris, Naunyn Schmiedebergs Arch Pharmacol, 354, 520, 10.1007/BF00168445
Chirkov, 1999, Nitrate resistance in platelets from patients with stable angina pectoris, Circulation, 100, 129, 10.1161/01.CIR.100.2.129
Chirkov, 2001, Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets, J Am Coll Cardiol, 37, 1851, 10.1016/S0735-1097(01)01238-4
Rajendran, 2008, Platelet hyperaggregability: impaired responsiveness to nitric oxide (“platelet NO resistance”) as a therapeutic target, Cardiovasc Drugs Ther, 22, 193, 10.1007/s10557-008-6098-7
Russo, 2007, Platelet resistance to the antiaggregatory cyclic nucleotides in central obesity involves reduced phosphorylation of vasodilator-stimulated phosphoprotein, Clin Chem, 53, 1053, 10.1373/clinchem.2006.076208
Berg, 2005, Adipose tissue, inflammation, and cardiovascular disease, Circ Res, 96, 939, 10.1161/01.RES.0000163635.62927.34
Trujillo, 2006, Adipose tissue-derived factors: impact on health and disease, Endocr Rev, 27, 762, 10.1210/er.2006-0033
Gómez-Ambrosi, 2006, Increased cardiovascular risk markers in obesity are associated with body adiposity: role of leptin, Thromb Haemost, 95, 991, 10.1160/TH06-02-0079
Söderberg, 1999, Leptin is associated with increased risk of myocardial infarction, J Intern Med, 246, 409, 10.1046/j.1365-2796.1999.00571.x
Wallace, 2001, Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS), Circulation, 104, 3052, 10.1161/hc5001.101061
Söderberg, 2003, High leptin levels are associated with stroke, Cerebrovasc Dis, 15, 63, 10.1159/000067128
Qasim, 2008, Adipokines, insulin resistance, and coronary artery calcification, J Am Coll Cardiol, 52, 231, 10.1016/j.jacc.2008.04.016
Reilly, 2004, Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes, J Clin Endocrinol Metab, 89, 3872, 10.1210/jc.2003-031676
Piatti, 2003, Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting, Circulation, 108, 2074, 10.1161/01.CIR.0000095272.67948.17
Piatti, 2005, Insulin resistance, hyperleptinemia and endothelial dysfunction in coronary restenosis, Curr Opin Pharmacol, 5, 160, 10.1016/j.coph.2004.10.004
Nakata, 1999, Leptin promotes aggregation of human platelets via the long form of its receptor, Diabetes, 48, 426, 10.2337/diabetes.48.2.426
Konstantinides, 2001, Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity, J Clin Invest, 108, 1533, 10.1172/JCI13143
Corsonello, 2003, Leptin-dependent platelet aggregation in healthy, overweight and obese subjects, Int J Obes Relat Metab Disord, 27, 566, 10.1038/sj.ijo.0802273
Elbatarny, 2005, Leptin-mediated activation of human platelets: involvement of a leptin receptor and phosphodiesterase 3A-containing cellular signaling complex, Am J Physiol Endocrinol Metab, 289, E695, 10.1152/ajpendo.00125.2005
Konstantinides, 2001, The prothrombotic effects of leptin possible implications for the risk of cardiovascular disease in obesity, Ann N Y Acad Sci, 947, 134, 10.1111/j.1749-6632.2001.tb03936.x
Dellas, 2007, Leptin signalling and leptin-mediated activation of human platelets: importance of JAK2 and the phospholipases Cgamma2 and A2, Thromb Haemost, 98, 1063, 10.1160/TH07-03-0213
El-Haschimi, 2003, Leptin resistance – or why leptin fails to work in obesity, Exp Clin Endocrinol Diabetes, 111, 2, 10.1055/s-2003-37492
Rahmouni, 2005, Role of selective leptin resistance in diet-induced obesity hypertension, Diabetes, 54, 2012, 10.2337/diabetes.54.7.2012
Kougias, 2005, Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease, J Surg Res, 126, 121, 10.1016/j.jss.2004.12.023
Darvall, 2007, Obesity and thrombosis, Eur J Vasc Endovasc Surg, 33, 223, 10.1016/j.ejvs.2006.10.006
Bełtowski, 2008, Adiponectin and its role in cardiovascular diseases, Cardiovasc Hematol Disord Drug Targets, 8, 7, 10.2174/187152908783884920
Elbatarny, 2007, Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implications in obesity-associated cardiovascular diseases, Eur J Pharmacol, 558, 7, 10.1016/j.ejphar.2006.11.052
Riba, 2008, Globular adiponectin induces platelet activation through the collagen receptor GPVI-Fc receptor gamma chain complex, J Thromb Haemost, 6, 1012, 10.1111/j.1538-7836.2008.02982.x
Bhagat, 1997, Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo, Circulation, 96, 3042, 10.1161/01.CIR.96.9.3042
Alessi, 2003, Adipose tissue and atherothrombosis, Pathophysiol Haemost Thromb, 33, 290, 10.1159/000083816
Lau, 2005, Adipokines: molecular links between obesity and atherosclerosis, Am J Physiol Heart Circ Physiol, 288, H2031, 10.1152/ajpheart.01058.2004
Peng, 1994, Alteration of platelet function in dogs mediated by interleukin-6, Blood, 83, 398, 10.1182/blood.V83.2.398.398
Peng, 1996, Relative reactivity of platelets from thrombopoietin- and interleukin-6-treated dogs, Blood, 87, 4158, 10.1182/blood.V87.10.4158.bloodjournal87104158
Lou, 1997, Platelets play an important role in TNF-induced microvascular endothelial cell pathology, Am J Pathol, 151, 1397
Nishimura, 2008, In vivo imaging in mice reveals local cell dynamics and inflammation in obese adipose tissue, J Clin Invest, 118, 710
Vincent, 2007, Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity, Diabetes Obes Metab, 9, 813, 10.1111/j.1463-1326.2007.00692.x
Pignatelli, 1998, Hydrogen peroxide is involved in collagen-induced platelet activation, Blood, 91, 484, 10.1182/blood.V91.2.484
Pulcinelli, 2001, Platelets and oxygen radicals: mechanisms of functional modulation, Haematologica, 86, 31
Wachowicz, 2002, Generation of reactive oxygen species in blood platelets, Platelets, 13, 175, 10.1080/09533710022149395
Begonja, 2005, Platelet NAD(P)H-oxidase-generated ROS production regulates alphaIIbbeta3-integrin activation independent of the NO/cGMP pathway, Blood, 106, 2757, 10.1182/blood-2005-03-1047
Morrow, 1990, A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism, Proc Natl Acad Sci U S A, 87, 9383, 10.1073/pnas.87.23.9383
Roberts, 2000, Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo, Free Radic Biol Med, 28, 505, 10.1016/S0891-5849(99)00264-6
Montuschi, 2004, Isoprostanes: markers and mediators of oxidative stress, FASEB J, 18, 1791, 10.1096/fj.04-2330rev
Milne, 2008, Human biochemistry of the isoprostane pathway, J Biol Chem, 283, 15533, 10.1074/jbc.R700047200
Patrono, 1997, Isoprostanes: potential markers of oxidant stress in atherothrombotic disease, Arterioscler Thromb Vasc Biol, 17, 2309, 10.1161/01.ATV.17.11.2309
Audoly, 2000, Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo, Circulation, 101, 2833, 10.1161/01.CIR.101.24.2833
Cipollone, 2000, Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina, Circulation, 102, 1007, 10.1161/01.CIR.102.9.1007
Praticò, 1996, Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms, J Biol Chem, 271, 14916, 10.1074/jbc.271.25.14916
Khasawneh, 2008, Characterization of isoprostane signaling: evidence for a unique coordination profile of 8-iso-PGF(2alpha) with the thromboxane A(2) receptor, and activation of a separate cAMP-dependent inhibitory pathway in human platelets, Biochem Pharmacol, 75, 2301, 10.1016/j.bcp.2008.03.014
Davì, 1997, Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease, Circulation, 96, 69, 10.1161/01.CIR.96.1.69
Keaney, 2003, Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study, Arterioscler Thromb Vasc Biol, 23, 434, 10.1161/01.ATV.0000058402.34138.11
Tendera, 2003, Role of antiplatelet drugs in the prevention of cardiovascular events, Thromb Res, 110, 355, 10.1016/j.thromres.2003.08.003
Tamminen, 2003, Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects, Int J Obes Relat Metab Disord, 27, 907, 10.1038/sj.ijo.0802312
Cohen, 2008, Aspirin resistance associated with HbA1c and obesity in diabetic patients, J Diabetes Complications, 22, 224, 10.1016/j.jdiacomp.2007.05.002
Sacco, 2003, Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial, Diabetes Care, 26, 3264, 10.2337/diacare.26.12.3264
Davì, 1999, In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation, Circulation, 99, 224, 10.1161/01.CIR.99.2.224
Hollopeter, 2001, Identification of the platelet ADP receptor targeted by antithrombotic drugs, Nature, 409, 202, 10.1038/35051599
Angiolillo, 2004, Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?, J Invasive Cardiol, 16, 169
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486
Daskalopoulou, 2004, Prevention and treatment of the metabolic syndrome, Angiology, 55, 589, 10.1177/00033197040550i601
Getz, 2007, Nutrition and cardiovascular disease, Arterioscler Thromb Vasc Biol, 27, 2499, 10.1161/ATVBAHA.107.155853
Giugliano, 2008, Mediterranean diet and metabolic diseases, Curr Opin Lipidol, 19, 63, 10.1097/MOL.0b013e3282f2fa4d
Rauramaa, 1999, Interaction of physical activity and diet: implications for haemostatic factors, Public Health Nutr, 2, 383, 10.1017/S136898009900052X
Coban, 2007, The effect of weight loss on the mean platelet volume in obese patients, Platelets, 18, 212, 10.1080/09537100600975362
Formoso, 2008, Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects, Diabetes Metab Res, 24, 231, 10.1002/dmrr.794
Borchert, 2007, Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function, Diabetes Technol Ther, 9, 410, 10.1089/dia.2007.0224
Ferroni, 2006, Low-density lipoprotein-lowering medication and platelet function, Pathophysiol Haemost Thromb, 35, 346, 10.1159/000093226
Moreno, 2004, New aspects in the pathogenesis of diabetic atherothrombosis, J Am Coll Cardiol, 44, 2099, 10.1016/j.jacc.2004.06.077
Trovati, 2002, Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function, J Diabetes Complications, 16, 35, 10.1016/S1056-8727(01)00196-9
Hayden, 2003, Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress, Cardiovasc Diabetol, 2, 2, 10.1186/1475-2840-2-2
Ferroni, 2004, Platelet activation in type 2 diabetes mellitus, J Thromb Haemost, 2, 1282, 10.1111/j.1538-7836.2004.00836.x